915 related articles for article (PubMed ID: 33413355)
1. Empagliflozin does not change cardiac index nor systemic vascular resistance but rapidly improves left ventricular filling pressure in patients with type 2 diabetes: a randomized controlled study.
Rau M; Thiele K; Hartmann NK; Schuh A; Altiok E; Möllmann J; Keszei AP; Böhm M; Marx N; Lehrke M
Cardiovasc Diabetol; 2021 Jan; 20(1):6. PubMed ID: 33413355
[TBL] [Abstract][Full Text] [Related]
2. Effect of Empagliflozin on Left Ventricular Mass in Patients With Type 2 Diabetes Mellitus and Coronary Artery Disease: The EMPA-HEART CardioLink-6 Randomized Clinical Trial.
Verma S; Mazer CD; Yan AT; Mason T; Garg V; Teoh H; Zuo F; Quan A; Farkouh ME; Fitchett DH; Goodman SG; Goldenberg RM; Al-Omran M; Gilbert RE; Bhatt DL; Leiter LA; Jüni P; Zinman B; Connelly KA
Circulation; 2019 Nov; 140(21):1693-1702. PubMed ID: 31434508
[TBL] [Abstract][Full Text] [Related]
3. Empagliflozin and left ventricular diastolic function following an acute coronary syndrome in patients with type 2 diabetes.
Lan NSR; Yeap BB; Fegan PG; Green G; Rankin JM; Dwivedi G
Int J Cardiovasc Imaging; 2021 Feb; 37(2):517-527. PubMed ID: 32959096
[TBL] [Abstract][Full Text] [Related]
4. Impact of dapagliflozin on left ventricular diastolic function of patients with type 2 diabetic mellitus with chronic heart failure.
Soga F; Tanaka H; Tatsumi K; Mochizuki Y; Sano H; Toki H; Matsumoto K; Shite J; Takaoka H; Doi T; Hirata KI
Cardiovasc Diabetol; 2018 Oct; 17(1):132. PubMed ID: 30296931
[TBL] [Abstract][Full Text] [Related]
5. Positive effect of dapagliflozin on left ventricular longitudinal function for type 2 diabetic mellitus patients with chronic heart failure.
Tanaka H; Soga F; Tatsumi K; Mochizuki Y; Sano H; Toki H; Matsumoto K; Shite J; Takaoka H; Doi T; Hirata KI
Cardiovasc Diabetol; 2020 Jan; 19(1):6. PubMed ID: 31910853
[TBL] [Abstract][Full Text] [Related]
6. Effect of Empagliflozin as an Add-On Therapy on Decongestion and Renal Function in Patients With Diabetes Hospitalized for Acute Decompensated Heart Failure: A Prospective Randomized Controlled Study.
Tamaki S; Yamada T; Watanabe T; Morita T; Furukawa Y; Kawasaki M; Kikuchi A; Kawai T; Seo M; Abe M; Nakamura J; Yamamoto K; Kayama K; Kawahira M; Tanabe K; Fujikawa K; Hata M; Fujita Y; Umayahara Y; Taniuchi S; Sanada S; Shintani A; Fukunami M
Circ Heart Fail; 2021 Mar; 14(3):e007048. PubMed ID: 33663235
[TBL] [Abstract][Full Text] [Related]
7. Rationale and Design of the EMPA-TROPISM Trial (ATRU-4): Are the "Cardiac Benefits" of Empagliflozin Independent of its Hypoglycemic Activity?
Santos-Gallego CG; Garcia-Ropero A; Mancini D; Pinney SP; Contreras JP; Fergus I; Abascal V; Moreno P; Atallah-Lajam F; Tamler R; Lala A; Sanz J; Fuster V; Badimon JJ
Cardiovasc Drugs Ther; 2019 Feb; 33(1):87-95. PubMed ID: 30675708
[TBL] [Abstract][Full Text] [Related]
8. Associations of Empagliflozin With Left Ventricular Volumes, Mass, and Function in Patients With Heart Failure and Reduced Ejection Fraction: A Substudy of the Empire HF Randomized Clinical Trial.
Omar M; Jensen J; Ali M; Frederiksen PH; Kistorp C; Videbæk L; Poulsen MK; Tuxen CD; Möller S; Gustafsson F; Køber L; Schou M; Møller JE
JAMA Cardiol; 2021 Jul; 6(7):836-840. PubMed ID: 33404637
[TBL] [Abstract][Full Text] [Related]
9. Effect of Empagliflozin on Left Ventricular Volumes in Patients With Type 2 Diabetes, or Prediabetes, and Heart Failure With Reduced Ejection Fraction (SUGAR-DM-HF).
Lee MMY; Brooksbank KJM; Wetherall K; Mangion K; Roditi G; Campbell RT; Berry C; Chong V; Coyle L; Docherty KF; Dreisbach JG; Labinjoh C; Lang NN; Lennie V; McConnachie A; Murphy CL; Petrie CJ; Petrie JR; Speirits IA; Sourbron S; Welsh P; Woodward R; Radjenovic A; Mark PB; McMurray JJV; Jhund PS; Petrie MC; Sattar N
Circulation; 2021 Feb; 143(6):516-525. PubMed ID: 33186500
[TBL] [Abstract][Full Text] [Related]
10. Effects of empagliflozin in different phases of diabetes mellitus-related cardiomyopathy: a prospective observational study.
Oka S; Kai T; Hoshino K; Watanabe K; Nakamura J; Abe M; Watanabe A
BMC Cardiovasc Disord; 2021 Apr; 21(1):217. PubMed ID: 33926386
[TBL] [Abstract][Full Text] [Related]
11. Empagliflozin and Clinical Outcomes in Patients With Type 2 Diabetes Mellitus, Established Cardiovascular Disease, and Chronic Kidney Disease.
Wanner C; Lachin JM; Inzucchi SE; Fitchett D; Mattheus M; George J; Woerle HJ; Broedl UC; von Eynatten M; Zinman B;
Circulation; 2018 Jan; 137(2):119-129. PubMed ID: 28904068
[TBL] [Abstract][Full Text] [Related]
12. Empagliflozin in heart failure patients with reduced ejection fraction: a randomized clinical trial (Empire HF).
Jensen J; Omar M; Kistorp C; Poulsen MK; Tuxen C; Gustafsson I; Køber L; Gustafsson F; Fosbøl E; Bruun NE; Videbæk L; Frederiksen PH; Møller JE; Schou M
Trials; 2019 Jun; 20(1):374. PubMed ID: 31227014
[TBL] [Abstract][Full Text] [Related]
13. Impact of empagliflozin on right ventricular parameters and function among patients with type 2 diabetes.
Sarak B; Verma S; David Mazer C; Teoh H; Quan A; Gilbert RE; Goodman SG; Bami K; Coelho-Filho OR; Ahooja V; Deva DP; Garg V; Gandhi S; Connelly KA; Yan AT
Cardiovasc Diabetol; 2021 Oct; 20(1):200. PubMed ID: 34607574
[TBL] [Abstract][Full Text] [Related]
14. Reduction of estimated fluid volumes following initiation of empagliflozin in patients with type 2 diabetes and cardiovascular disease: a secondary analysis of the placebo-controlled, randomized EMBLEM trial.
Tanaka A; Shimabukuro M; Teragawa H; Okada Y; Takamura T; Taguchi I; Toyoda S; Tomiyama H; Ueda S; Higashi Y; Node K;
Cardiovasc Diabetol; 2021 Jun; 20(1):105. PubMed ID: 34183012
[TBL] [Abstract][Full Text] [Related]
15. Empagliflozin and the Risk of Heart Failure Hospitalization in Routine Clinical Care.
Patorno E; Pawar A; Franklin JM; Najafzadeh M; Déruaz-Luyet A; Brodovicz KG; Sambevski S; Bessette LG; Santiago Ortiz AJ; Kulldorff M; Schneeweiss S
Circulation; 2019 Jun; 139(25):2822-2830. PubMed ID: 30955357
[TBL] [Abstract][Full Text] [Related]
16. Randomized Trial of Empagliflozin in Nondiabetic Patients With Heart Failure and Reduced Ejection Fraction.
Santos-Gallego CG; Vargas-Delgado AP; Requena-Ibanez JA; Garcia-Ropero A; Mancini D; Pinney S; Macaluso F; Sartori S; Roque M; Sabatel-Perez F; Rodriguez-Cordero A; Zafar MU; Fergus I; Atallah-Lajam F; Contreras JP; Varley C; Moreno PR; Abascal VM; Lala A; Tamler R; Sanz J; Fuster V; Badimon JJ;
J Am Coll Cardiol; 2021 Jan; 77(3):243-255. PubMed ID: 33197559
[TBL] [Abstract][Full Text] [Related]
17. How does empagliflozin improve arterial stiffness in patients with type 2 diabetes mellitus? Sub analysis of a clinical trial.
Bosch A; Ott C; Jung S; Striepe K; Karg MV; Kannenkeril D; Dienemann T; Schmieder RE
Cardiovasc Diabetol; 2019 Mar; 18(1):44. PubMed ID: 30922297
[TBL] [Abstract][Full Text] [Related]
18. Rationale and design of the effects of EMpagliflozin on left ventricular DIAstolic function in diabetes (EmDia) study.
Jünger C; Prochaska JH; Gori T; Schulz A; Binder H; Daiber A; Koeck T; Rapp S; Lackner KJ; Münzel T; Wild PS
J Cardiovasc Med (Hagerstown); 2022 Mar; 23(3):191-197. PubMed ID: 34939776
[TBL] [Abstract][Full Text] [Related]
19. Effects of empagliflozin on erythropoiesis in patients with type 2 diabetes: Data from a randomized, placebo-controlled study.
Thiele K; Rau M; Hartmann NK; Möllmann J; Jankowski J; Böhm M; Keszei AP; Marx N; Lehrke M
Diabetes Obes Metab; 2021 Dec; 23(12):2814-2818. PubMed ID: 34378852
[TBL] [Abstract][Full Text] [Related]
20. Effects of the SGLT2 inhibitor dapagliflozin on cardiac function evaluated by impedance cardiography in patients with type 2 diabetes. Secondary analysis of a randomized placebo-controlled trial.
Bonora BM; Vigili de Kreutzenberg S; Avogaro A; Fadini GP
Cardiovasc Diabetol; 2019 Aug; 18(1):106. PubMed ID: 31412874
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
